HC Wainwright Brokers Increase Earnings Estimates for TPST

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for Tempest Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.34) for the year, up from their previous forecast of ($2.76). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($0.89) EPS.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.62) EPS for the quarter, meeting analysts’ consensus estimates of ($0.62).

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $12.50.

Tempest Therapeutics Trading Down 1.9%

Shares of NASDAQ:TPST opened at $1.59 on Friday. The stock’s 50-day moving average price is $2.28 and its two-hundred day moving average price is $5.10. Tempest Therapeutics has a 12-month low of $1.50 and a 12-month high of $12.23. The firm has a market cap of $7.84 million, a price-to-earnings ratio of -0.24 and a beta of -2.00.

Insider Activity

In related news, CEO Matthew Angel acquired 231,482 shares of the stock in a transaction dated Tuesday, March 24th. The stock was bought at an average cost of $2.16 per share, with a total value of $500,001.12. Following the purchase, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tempest Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics during the fourth quarter valued at about $33,000. Vanguard Group Inc. raised its holdings in shares of Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after purchasing an additional 27,952 shares during the period. Finally, Sabby Management LLC acquired a new position in shares of Tempest Therapeutics in the 4th quarter valued at about $513,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.